FirstWord's Duncan Emerton (Senior Director, Syndicated Insights & Analysis) and Simon King (Executive Editor, FirstWord Pharma PLUS) discuss the implications of new rheumatoid arthritis guidance issued by the UK's NICE - in particular its impact on the biosimilar infliximab market.
To read more The First Take articles, click here.
About FirstWord Pharma | Upgrade Your FirstWord Pharma | Contact FirstWord Pharma | FirstWord Reports
Advertise with FirstWord Pharma | Industry Partner Showcase
All Contents Copyright © 2021 Doctor's Guide Publishing Limited. All Rights Reserved.
Terms of Use | Privacy Policy